IfW

Patent Application Attorney Docket No.PC23199A

Examiner:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28th day of September, 2004.

signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Steven W. Collier, et al.

APPLICATION NO.: 10/636,013

FILING DATE: August 6, 2003 : Group Art Unit: 1616

TITLE: STABLE NON-DIHYDRATE

AZITHROMYCIN ORAL SUSPENSIONS

Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 27 September 2004

Scott Alexander McNeil Attorney for Applicant(s)

Reg. No. 37,185

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340

(860) 686-1848

#71984 v1 - PC23199A INFORMATION DISCLOSURE STATEMENT

INFOR	MATI	SAPPAR	CLOSI	JRE CI	TATION	I AT	TY. DOC	CKET N	O. PC2319	99A	SERIAL NO	. 10/63	6,013	3
(Use several sheets if necessary)					AP	APPLICANT Steven W. Collier, et al.								
·						FIL	ING DA	TE Aug	ust 6, 2003	3	GROUP	1616		
						U.S	. PATEN	IT DOC	UMENTS	-	· · · · · · · · · · · · · · · · · · ·			
CAMINER INITIAL				DOC	UMENT NUI	MBER		·	DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIA
	us	4	4	7	4	7	6	9	10/2/84	Bright	424	180		
	US	6	3	6	5	5	7	4	4/2/02	Singer, et a	ıl. 514	29		
	US	6	2	4	5	9	0	9	6/12/01	Karimian, et	al. 536	7.4		
	us	6	2	6	8	4	8	9	7/31/01	Allen, et al	. 536	7.4		
	us	4	5	6		5	3	1	10/16/90	Remingtor	514	29		
	us	6	5	0	5	8	3	9	2/25/97	Curatolo, et	al. 514	29		
						FORE	IGN PAT	ENT D	OCUMENT	гѕ				
- 72-12-1		DOCUMENT NUMBER							DATE COUNTRY		CLASS	SUBCLASS	TRANSLATIO	
				1		I	1						YES	NO
	wo	0	4	0	0	8	6	5	12/31/03	Internation	al C07H	17/08		
	wo	0	0	5	7	8	8	6	5/10/00	Internationa	al A61K	31/70	х	
			ОТН	ER DO	CUMEN	TS (In	cluding A	luthor,	Title, Date,	Pertinent Pa	ges, Etc.)			
		Zheng	Li, et al.	, U.S. Pat	ent Applic	cation Se	erial Numbe	er (USSN) 10/152,106,	Publication No.	2003-0162730A	1, published	on 8/2	8/03
		Zheng Li, et al., U.S. Patent Application Serial Number (USSN) 10/152,106, Publication No. 2003-0162730A1, published on 8/28/03 Ofner, C., et al., "Suspensions", FMC BioPolymer, Section 9, pp.1-22 (2000) Dell, S., et al., "Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcellulose Sodium, NF, BP", FMC BioPolymer, Section 14. pp. 1-27 (2001) Weissbuch, I, et al., "Understanding and Control of Nucleation, Growth, Habit, Dissolution and Structure of Two- and Three-Dimensional Crystals Using 'Tailor-Made' Auxiliaries", Acta Cryst., Vol. B51, pp. 115-148 (1995)												
										tion				
		Ebian, A., et al., "Effect of additives on the kinetics of interconversation of sulphamethoxydiazine crystal forms", <i>J. Pharm. Pharma</i> Vol. 25, pp. 13-20 (1973)									mac			
		Miyazaki, S., "Effect of Additives on the Polymorphic Transformation of Chlortetracycline Hydrochloride Crystals", Chem. Pharm. Bull., Vo. 24(9), pp. 2094-2101 (12976)												
	Ziller, K.H., et al., "Control of Crystal Growth in Drug Suspensions", Pharm. Ztg. Wiss., NR. 4-3/135. pp. 147-152 (1990)													
		Shefter, E., "Dissolution Behavior of Crystalline Solvated and Nonsolvated Forms of Some Pharmaceuticals", <i>Journal of Pharmaceutical Sciences</i> , Vol. 52., No. 8, pp. 781-791 (1963)												
		Otsuka Surfac	a, M., et a ces B; Bio	al., "Effect ointerface:	of binders, Vol. 17	s on pol	ymorphic tr -152 (2000	ransforma	ation kinetics	of carbamazepin	e in aqueous so	lution", Colla	ids and	d
		Horn,	D., et al.,	"Interacti	on betwe	en polyv		one and o		raisal of its signi	ficance for GI dr	ug absorptio	n",	

INF	ORMATI	ON DISCLOSURE CITATION	ATTY. DOCKET NO. PC23199A	SERIAL NO.	10/636,013						
	(Use se	veral sheets if necessary)	APPLICANT Steven W. Collier,	et al.							
	· ·		FILING DATE August 6, 2003	GROUP	1616						
01	PE	Johnson, B., et al., "Effects of Surfac 17, pp. 325-342 (1986)	tants and Polymers on Advancing and Reced	ling Contact Angles", Colloids	s and Surfaces, Vol.						
SEP 3	0 2004		sion of Sodium Dodecylsulfate Solutions and terface Science, Vol. 21, pp. 331-347 (1966)	the Phase Separation Mode	l of Michelle						
CHA!	0 2004 DEMO	Askar, A., "A Review on Sweeteners"	, <i>Nutrition</i> , Vol. 12, Nr. 11, pp. 706-712 (1988	3)							
		Parsons, D., "Carboxymethylcellulose	e Sodium", Handbook of Pharmaceutical Exc.	ipients, 3 rd Edition, pp. 87-90							
		Goskonda, S.R., et al., "Cellulose Acetate Phthalate", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 99-101 Malick, A.W., "Docusate Sodium", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 188-190 Hogan, J.E., "Coloring Agents", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 146-153 Harwood, R.J., "Hydroxypropyl Cellulose", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 244-248									
	 										
	Harwood, R.J., "Hydroxypropyl Methylcellulose", Handbook of Pharmaceutical Excipients, 3rd Edition, pp. 252-255										
		Kibbe, A.H., "Povidone", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 433-439 Russell, G., et al., "Saccharin", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 454-456									
		Russell, G., et al., "Saccharine Sodium", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 457-459									
		Behn, S., "Sodium Lauryl Sulfate", Ha	andbook of Pharmaceutical Excipients, 3 rd Ed	Excipients, 3 rd Edition, pp. 487-489							
		Behn, S., "Sodium Phosphate, Dibasic", Handbook of Pharmaceutical Excipients, 3rd Edition, Sections 12-19, p.494									
Armstrong, N.A., et al., "Sucrose", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 539-543 Daskalakis, S.A., "Xanthan Gum", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 599-601											
									<u> </u>	Handbook of Pharmaceutical Additive	es, pp. 120; 214; 351; 484-485; 557; 558; 610
	INER		DATE CONSIDERED								

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE